<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486625</url>
  </required_header>
  <id_info>
    <org_study_id>C3601006</org_study_id>
    <nct_id>NCT04486625</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment</brief_title>
  <official_title>AN OPEN-LABEL, PARALLEL-GROUP, PHARMACOKINETIC STUDY OF MULTIPLE INTRAVENOUS DOSES OF AZTREONAM AND AVIBACTAM IN SUBJECTS WITH SEVERE RENAL IMPAIRMENT AND NORMAL RENAL FUNCTION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study is being conducted to evaluate the effect of severe renal impairment on&#xD;
      the PK, safety and tolerability of Aztreonam-Avibactam. Results from this study along with&#xD;
      previous renal impairment data from each of the Aztreonam-Avibactam components will be used&#xD;
      to confirm the proposed dosing adjustment in severe renal impairment which was based on&#xD;
      modelling/simulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2020</start_date>
  <completion_date type="Actual">October 18, 2021</completion_date>
  <primary_completion_date type="Actual">September 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-24,ss</measure>
    <time_frame>Day 3</time_frame>
    <description>Total daily area under the plasma concentration time profile from time 0 to 24 hours at steady-state (AUC0-24,ss)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 3</time_frame>
    <description>Maximum Observed Plasma Concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-tau</measure>
    <time_frame>Day 3</time_frame>
    <description>Area under the plasma concentration-time profile from time 0 to the end of the dosing interval (tau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 3</time_frame>
    <description>Time of observed maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctau</measure>
    <time_frame>Day 3</time_frame>
    <description>Observed plasma concentration at the end of the dosing interval (tau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Day 3</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>Day 3</time_frame>
    <description>Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLr</measure>
    <time_frame>Day 3</time_frame>
    <description>Renal clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz</measure>
    <time_frame>Day 3</time_frame>
    <description>Apparent Volume of distribution during terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss</measure>
    <time_frame>Day 3</time_frame>
    <description>Apparent volume of distribution at steady-state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae0-tau</measure>
    <time_frame>Day 3</time_frame>
    <description>Total amount of unchanged drug excreted in urine over a dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae0-tau%</measure>
    <time_frame>Day 3</time_frame>
    <description>Total amount of unchanged drug excreted in urine over a dosing interval expressed as percent of dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>Days 1 to 3</time_frame>
    <description>Number (%) of participants reporting an adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ECG parameters</measure>
    <time_frame>Days 1 to 3</time_frame>
    <description>Number (%) of participants with maximum postdose QTc values and maximum increases that are categorized as borderline or prolonged</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe renal impairment (not on dialysis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aztreonam-Avibactam</intervention_name>
    <description>500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aztreonam-Avibactam</intervention_name>
    <description>675/225 mg ATM/AVI loading infusion, followed by 675/225 mg ATM/AVI extended loading infusion, then 675/225 mg ATM/AVI maintenance dose infusion every 8 hours</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy female subjects and/or male subjects between the ages of 18 and 75 years,&#xD;
             inclusive. Male and female subjects of childbearing potential must agree to use highly&#xD;
             effective method(s) of contraception&#xD;
&#xD;
          -  Body mass index (BMI) of 17.5 to 40.5 kg/m2; and a total body weight &gt;50 kg (110 lb)&#xD;
&#xD;
          -  Stable renal function defined as &lt;/=25% difference between 2 measurements of eGFR&#xD;
             obtained on 2 separate occasions during the screening period that are at least 72&#xD;
             hours but no more than 14 days apart Specific Requirements for Healthy Subjects with&#xD;
             Normal Renal Function&#xD;
&#xD;
          -  Normal renal function (eGFR&gt;/= 80 mL/min) at Screening based on the Day -2 value,&#xD;
             using the MDRD formula adjusting for BSA&#xD;
&#xD;
          -  Demographically comparable to the group of subjects with severe impaired renal&#xD;
             function Specific Requirements for Subjects with Severe Renal Impairment&#xD;
&#xD;
          -  Good general health commensurate with the population with chronic kidney disease.&#xD;
&#xD;
          -  Documented severe renal impairment indicated by eGFR &gt;15 -&lt;/=30 mL/min but not&#xD;
             requiring hemodialysis, using the MDRD formula adjusting for BSA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive urine drug test&#xD;
&#xD;
          -  History of regular alcohol use (within 6 months) exceeding 7 drinks/week for female or&#xD;
             14 drinks/week for male subjects&#xD;
&#xD;
          -  Treatment with an investigational product within 30 days or 5 half-lives preceding the&#xD;
             first dose of investigational product (whichever is longer)&#xD;
&#xD;
          -  Subjects with abnormalities in clinical laboratory tests (AST, ALT, Total bilirubin,&#xD;
             aPTT, PT, INR) at Screening&#xD;
&#xD;
          -  Pregnant females; breastfeeding females; fertile male subjects and female subjects of&#xD;
             childbearing potential who are unwilling or unable to use a highly effective method of&#xD;
             contraception&#xD;
&#xD;
          -  Use of prescription or nonprescription drugs and dietary supplements within 7 days or&#xD;
             5 half-lives (whichever is longer) prior to the first dose of investigational product.&#xD;
             For subjects with severe renal impairment, concomitant medications may be given if&#xD;
             considered necessary for the subject welfare (eg, standard therapy for underlying&#xD;
             diseases), are not contraindicated with the study drug, and are unlikely to interfere&#xD;
             with the PK/PD response of the study drug. Use of oral anticoagulants and potent&#xD;
             inhibitors of OAT1 and/or OAT3 (eg, probenecid) are prohibited in all subjects.&#xD;
&#xD;
          -  Blood donation (excluding plasma donations) of approximately 1 pint or more within 60&#xD;
             days prior to dosing&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia&#xD;
&#xD;
          -  History of serious allergy, hypersensitivity or any serious reaction to aztreonam,&#xD;
             carbapenem, monobactam or other beta-lactam antibiotics, avibactam, or any of the&#xD;
             excipients of the respective (investigational) medicinal products&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C&#xD;
&#xD;
          -  Other acute or chronic medical or psychiatric condition&#xD;
&#xD;
          -  Past or current history of epilepsy or seizure disorders excluding febrile seizures of&#xD;
             childhood Exclusion criteria: Subjects with Severe Renal Impairment&#xD;
&#xD;
          -  Any significant hepatic, cardiac, or pulmonary disease&#xD;
&#xD;
          -  Renal allograft recipients or subjects who are clinically nephrotic&#xD;
&#xD;
          -  Subjects requiring dialysis&#xD;
&#xD;
          -  Screening supine 12-lead ECG demonstrating QT interval corrected by Fridericia's&#xD;
             formula (QTcF) &gt;470 msec or a QRS interval &gt;120 msec&#xD;
&#xD;
          -  Screening supine BP &gt;/=180 millimeters of mercury (mm Hg) (systolic) or &gt;/=110 mm Hg&#xD;
             (diastolic), on a single measurement (confirmed by a single repeat, if necessary)&#xD;
             following at least 5 minutes of rest Exclusion criteria: Subjects with Normal Renal&#xD;
             Function&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or&#xD;
             allergic disease (including clinically relevant and significant drug allergies, but&#xD;
             excluding untreated, asymptomatic, seasonal allergies at time of dosing)&#xD;
&#xD;
          -  Screening supine 12-lead ECG demonstrating QTcF &gt;450 msec or a QRS interval &gt;120 msec&#xD;
&#xD;
          -  Screening supine BP &gt;/=140 mm Hg (systolic) or &gt;/=90 mm Hg (diastolic), following at&#xD;
             least 5 minutes of supine rest&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prism Research LLC dba Nucleus Network</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3601006</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aztreonam</mesh_term>
    <mesh_term>Avibactam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

